Efficacy and Safety of RTH258 Versus Aflibercept - Study 1

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection at two dosage levels (3 mg and 6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.
Epistemonikos ID: 6c33e8a0f38a76c869984ee9f9e05784a725f1ba
First added on: May 12, 2024